{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,19]],"date-time":"2026-03-19T23:39:22Z","timestamp":1773963562304,"version":"3.50.1"},"reference-count":43,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,2,1]],"date-time":"2026-02-01T00:00:00Z","timestamp":1769904000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,2,1]],"date-time":"2026-02-01T00:00:00Z","timestamp":1769904000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,12,22]],"date-time":"2025-12-22T00:00:00Z","timestamp":1766361600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["18X107CF5"],"award-info":[{"award-number":["18X107CF5"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000060","name":"National Institute of Allergy and Infectious Diseases","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000060","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000265","name":"UK Research and Innovation Medical Research Council","doi-asserted-by":"publisher","award":["MRC_UU_12023\/23"],"award-info":[{"award-number":["MRC_UU_12023\/23"]}],"id":[{"id":"10.13039\/501100000265","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Contemporary Clinical Trials Communications"],"published-print":{"date-parts":[[2026,2]]},"DOI":"10.1016\/j.conctc.2025.101592","type":"journal-article","created":{"date-parts":[[2025,12,24]],"date-time":"2025-12-24T08:14:39Z","timestamp":1766564079000},"page":"101592","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["Type I error control and interim monitoring for co-primary hypotheses involving a subgroup in the Outpatient Treatment with Anti-Coronavirus Immunoglobulin (OTAC) trial"],"prefix":"10.1016","volume":"49","author":[{"ORCID":"https:\/\/orcid.org\/0009-0004-3107-662X","authenticated-orcid":false,"given":"Jiayi","family":"Hu","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Abdel G.","family":"Babiker","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Cavan S.","family":"Reilly","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jason V.","family":"Baker","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9440-9146","authenticated-orcid":false,"given":"Lianne K.","family":"Siegel","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.conctc.2025.101592_b1","doi-asserted-by":"crossref","first-page":"972","DOI":"10.1016\/S2213-2600(22)00215-6","article-title":"Tixagevimab\u2013cilgavimab for treatment of patients hospitalised with COVID-19: a randomised, double-blind, phase 3 trial","volume":"10","author":"Holland","year":"2022","journal-title":"Lancet Respir. Med."},{"key":"10.1016\/j.conctc.2025.101592_b2","doi-asserted-by":"crossref","first-page":"262","DOI":"10.1038\/ncprheum0481","article-title":"Monoclonal antibody and intravenous immunoglobulin therapy for rheumatic diseases: rationale and mechanisms of action","volume":"3","author":"Bayry","year":"2007","journal-title":"Nat. Clin. Pr. Rheumatol."},{"issue":"4545","key":"10.1016\/j.conctc.2025.101592_b3","article-title":"Monoclonal antibody levels and protection from COVID-19","volume":"14","author":"Stadler","year":"2023","journal-title":"Nat. Commun."},{"key":"10.1016\/j.conctc.2025.101592_b4","doi-asserted-by":"crossref","first-page":"942","DOI":"10.1016\/S1473-3099(22)00365-6","article-title":"Neutralisation sensitivity of SARS-CoV-2 omicron subvariants to therapeutic monoclonal antibodies","volume":"22","author":"Yamasoba","year":"2022","journal-title":"Lancet Infect. Dis."},{"key":"10.1016\/j.conctc.2025.101592_b5","doi-asserted-by":"crossref","first-page":"874","DOI":"10.1007\/s13311-022-01222-x","article-title":"Therapeutic monoclonal antibody therapies in chronic autoimmune demyelinating neuropathies","volume":"19","author":"Briani","year":"2022","journal-title":"Neurotherapeutics"},{"key":"10.1016\/j.conctc.2025.101592_b6","article-title":"Polyclonal and monoclonal antibodies for induction therapy in kidney transplant recipients","volume":"1","author":"Hill","year":"2017","journal-title":"Cochrane Database Syst. Rev."},{"key":"10.1016\/j.conctc.2025.101592_b7","doi-asserted-by":"crossref","DOI":"10.1002\/ctm2.1046","article-title":"Monoclonal antibody-mediated immunosuppression enables long-term survival of transplanted human neural stem cells in mouse brain","volume":"12","author":"McGinley","year":"2022","journal-title":"Clin. Transl. Med."},{"key":"10.1016\/j.conctc.2025.101592_b8","doi-asserted-by":"crossref","first-page":"685","DOI":"10.1080\/14737140.2023.2213891","article-title":"First-line treatment of multiple myeloma in both transplant and non-transplant candidates","volume":"23","author":"Oriol","year":"2023","journal-title":"Expert. Rev. Anticancer. Ther."},{"key":"10.1016\/j.conctc.2025.101592_b9","doi-asserted-by":"crossref","first-page":"995","DOI":"10.2217\/imt.09.67","article-title":"Intravenous immunoglobulin-based immunotherapy: an arsenal of possibilities for patients and science","volume":"1","author":"Kotlan","year":"2009","journal-title":"Immunotherapy"},{"key":"10.1016\/j.conctc.2025.101592_b10","doi-asserted-by":"crossref","first-page":"535","DOI":"10.1016\/j.autrev.2019.03.010","article-title":"Immunoglobulin replacement for secondary immunodeficiency after B-cell targeted therapies in autoimmune rheumatic disease: Systematic literature review","volume":"18","author":"Wijetilleka","year":"2019","journal-title":"Autoimmun. Rev."},{"key":"10.1016\/j.conctc.2025.101592_b11","doi-asserted-by":"crossref","first-page":"3044","DOI":"10.3390\/curroncol29050247","article-title":"Immune checkpoint inhibitors in cancer therapy","volume":"29","author":"Shiravand","year":"2022","journal-title":"Curr. Oncol."},{"key":"10.1016\/j.conctc.2025.101592_b12","doi-asserted-by":"crossref","first-page":"641","DOI":"10.1038\/s41584-022-00841-0","article-title":"Immune-checkpoint inhibitor use in patients with cancer and pre-existing autoimmune diseases","volume":"18","author":"Tison","year":"2022","journal-title":"Nat. Rev. Rheumatol."},{"key":"10.1016\/j.conctc.2025.101592_b13","series-title":"Global Monoclonal Antibodies Market was Valued At US $208.32 Bn in 2022 and Is Expected To Hit a Revenue of US $647 Bn At CAGR of 12% Between Forecast Period of 2022-32","author":"Newswire","year":"2022"},{"key":"10.1016\/j.conctc.2025.101592_b14","series-title":"Immunoglobulin Market Trends \u2013 Analysis Report","first-page":"2032","year":"2023"},{"key":"10.1016\/j.conctc.2025.101592_b15","doi-asserted-by":"crossref","first-page":"238","DOI":"10.1056\/NEJMoa2035002","article-title":"REGN-COV2, a neutralizing antibody cocktail, in outpatients with COVID-19","volume":"384","author":"Weinreich","year":"2021","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.conctc.2025.101592_b16","doi-asserted-by":"crossref","DOI":"10.1056\/NEJMoa2108163","article-title":"REGEN-COV antibody combination and outcomes in outpatients with COVID-19","volume":"385","author":"Weinreich","year":"2021","journal-title":"N. Engl. J. Med."},{"issue":"10","key":"10.1016\/j.conctc.2025.101592_b17","doi-asserted-by":"crossref","first-page":"905","DOI":"10.1056\/NEJMoa2033130","article-title":"A neutralizing monoclonal antibody for hospitalized patients with Covid-19","volume":"384","author":"ACTIV-3\/TICO LY-CoV555 Study Group","year":"2021","journal-title":"N. Engl. J. Med."},{"issue":"9","key":"10.1016\/j.conctc.2025.101592_b18","doi-asserted-by":"crossref","first-page":"1266","DOI":"10.7326\/M22-1503","article-title":"Efficacy and safety of ensovibep for adults hospitalized with COVID-19","volume":"175","author":"ACTIV-3\/TICO Study Group","year":"2022","journal-title":"Ann. Intern. Med."},{"issue":"5","key":"10.1016\/j.conctc.2025.101592_b19","doi-asserted-by":"crossref","first-page":"622","DOI":"10.1016\/S1473-3099(21)00751-9","article-title":"Efficacy and safety of two neutralising monoclonal antibody therapies, sotrovimab and BRII-196 plus BRII-198, for adults hospitalised with COVID-19 (TICO): a randomised controlled trial","volume":"22","author":"Self","year":"2022","journal-title":"Lancet Infect. Dis."},{"issue":"2","key":"10.1016\/j.conctc.2025.101592_b20","doi-asserted-by":"crossref","first-page":"234","DOI":"10.7326\/M21-3507","article-title":"Responses to a neutralizing monoclonal antibody for hospitalized patients with COVID-19 according to baseline antibody and antigen levels","volume":"175","author":"ACTIV-3\/TICO Bamlanivimab Study Group","year":"2022","journal-title":"Ann. Intern. Med."},{"key":"10.1016\/j.conctc.2025.101592_b21","doi-asserted-by":"crossref","first-page":"726","DOI":"10.2105\/AJPH.86.5.726","article-title":"Adjusting for multiple testing when reporting research results: the Bonferroni vs Holm methods","volume":"86","author":"Aickin","year":"1996","journal-title":"Am. J. Public Health"},{"key":"10.1016\/j.conctc.2025.101592_b22","doi-asserted-by":"crossref","first-page":"665","DOI":"10.1016\/S0140-6736(22)00163-5","article-title":"Casirivimab and imdevimab in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial","volume":"399","author":"Abani","year":"2022","journal-title":"Lancet"},{"key":"10.1016\/j.conctc.2025.101592_b23","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1002\/pst.64","article-title":"A fixed sequence Bonferroni procedure for testing multiple endpoints","volume":"2","author":"Wiens","year":"2003","journal-title":"Pharm. Stat."},{"key":"10.1016\/j.conctc.2025.101592_b24","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1111\/j.2517-6161.1995.tb02031.x","article-title":"Controlling the false discovery rate: A practical and powerful approach to multiple testing","volume":"57","author":"Benjamini","year":"1995","journal-title":"J. R. Stat. Soc. Ser. B Stat. Methodol."},{"key":"10.1016\/j.conctc.2025.101592_b25","doi-asserted-by":"crossref","first-page":"767","DOI":"10.1002\/(SICI)1097-0258(20000330)19:6<767::AID-SIM518>3.0.CO;2-U","article-title":"Alpha calculus in clinical trials: considerations and commentary for the new millennium","volume":"19","author":"Moy\u00e9","year":"2000","journal-title":"Stat. Med."},{"issue":"3","key":"10.1016\/j.conctc.2025.101592_b26","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1002\/pst.291","article-title":"Gatekeeping procedures with clinical trial applications","volume":"6","author":"Dmitrienko","year":"2007","journal-title":"Pharm. Stat."},{"issue":"2","key":"10.1016\/j.conctc.2025.101592_b27","doi-asserted-by":"crossref","first-page":"494","DOI":"10.1093\/biomet\/ass002","article-title":"A generalized dunnett test for multi-arm multi-stage clinical studies with treatment selection","volume":"99","author":"Magirr","year":"2012","journal-title":"Biometrika"},{"issue":"6","key":"10.1016\/j.conctc.2025.101592_b28","doi-asserted-by":"crossref","first-page":"894","DOI":"10.1002\/bimj.201000239","article-title":"Graphical approaches for multiple comparison procedures using weighted Bonferroni, Simes or parametric tests","volume":"53","author":"Bretz","year":"2011","journal-title":"Biom. J."},{"key":"10.1016\/j.conctc.2025.101592_b29","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1080\/19466315.2013.807748","article-title":"Multiple testing in group sequential trials using graphical approaches","volume":"5","author":"Maurer","year":"2013","journal-title":"Stat. Biopharm. Res."},{"issue":"5","key":"10.1016\/j.conctc.2025.101592_b30","doi-asserted-by":"crossref","first-page":"918","DOI":"10.1002\/bimj.201600233","article-title":"A unified framework for weighted parametric multiple test procedures","volume":"59","author":"Xi","year":"2017","journal-title":"Biom. J."},{"key":"10.1016\/j.conctc.2025.101592_b31","doi-asserted-by":"crossref","first-page":"1219","DOI":"10.1002\/bimj.202100085","article-title":"A unified framework for weighted parametric group sequential design","volume":"64","author":"Anderson","year":"2022","journal-title":"Biom. J."},{"key":"10.1016\/j.conctc.2025.101592_b32","article-title":"Adjusted inference for multiple testing procedure in group-sequential designs","volume":"67","author":"Zhao","year":"2024","journal-title":"Biom. J."},{"issue":"5","key":"10.1016\/j.conctc.2025.101592_b33","doi-asserted-by":"crossref","first-page":"597","DOI":"10.1177\/1740774510381285","article-title":"Prospective alpha allocation in the clarification of optimal anticoagulation through genetics (COAG) trial","volume":"7","author":"Joo","year":"2010","journal-title":"Clin. Trials"},{"key":"10.1016\/j.conctc.2025.101592_b34","doi-asserted-by":"crossref","first-page":"3985","DOI":"10.1002\/sim.8216","article-title":"Adaptive group-sequential design with population enrichment in phase 3 randomized controlled trials with two binary co-primary endpoints","volume":"38","author":"Sinha","year":"2019","journal-title":"Stat. Med."},{"key":"10.1016\/j.conctc.2025.101592_b35","doi-asserted-by":"crossref","DOI":"10.1016\/j.cct.2020.106249","article-title":"Multiplicity for a group sequential trial with biomarker subpopulations","volume":"101","author":"Chen","year":"2021","journal-title":"Contemp. Clin. Trials"},{"key":"10.1016\/j.conctc.2025.101592_b36","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1016\/S0378-3758(99)00044-0","article-title":"Bayesian perspectives on multiple comparisons","volume":"82","author":"Berry","year":"1999","journal-title":"J. Statist. Plann. Inference"},{"key":"10.1016\/j.conctc.2025.101592_b37","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1200\/PO.19.00003","article-title":"Bayesian approaches to subgroup analysis and related adaptive clinical trial designs","volume":"3","author":"Nugent","year":"2019","journal-title":"JCO Precis. Oncol."},{"key":"10.1016\/j.conctc.2025.101592_b38","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1214\/20-BA1196","article-title":"Comparison of Bayesian and frequentist multiplicity correction for testing mutually exclusive hypotheses under data dependence","volume":"16","author":"Chang","year":"2021","journal-title":"Bayesian Anal."},{"issue":"440","key":"10.1016\/j.conctc.2025.101592_b39","doi-asserted-by":"crossref","first-page":"1342","DOI":"10.1080\/01621459.1997.10473655","article-title":"Semiparametric efficiency and its implication on the design and analysis of group-sequential studies","volume":"92","author":"Scharfstein","year":"1997","journal-title":"J. Amer. Statist. Assoc."},{"key":"10.1016\/j.conctc.2025.101592_b40","series-title":"Statistical Monitoring of Clinical Trials","author":"Proschan","year":"2006"},{"key":"10.1016\/j.conctc.2025.101592_b41","series-title":"Modern Applied Statistics with S","author":"Venables","year":"2002"},{"key":"10.1016\/j.conctc.2025.101592_b42","doi-asserted-by":"crossref","first-page":"950","DOI":"10.1198\/106186002394","article-title":"Package \u2018mvtnorm\u2019","volume":"11","author":"Genz","year":"2023","journal-title":"J. Comput. Graph. Statist."},{"key":"10.1016\/j.conctc.2025.101592_b43","series-title":"Package \u2018GsDesign\u2019","author":"Anderson","year":"2009"}],"container-title":["Contemporary Clinical Trials Communications"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2451865425001668?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2451865425001668?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,3,19]],"date-time":"2026-03-19T21:01:05Z","timestamp":1773954065000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2451865425001668"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2]]},"references-count":43,"alternative-id":["S2451865425001668"],"URL":"https:\/\/doi.org\/10.1016\/j.conctc.2025.101592","relation":{},"ISSN":["2451-8654"],"issn-type":[{"value":"2451-8654","type":"print"}],"subject":[],"published":{"date-parts":[[2026,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Type I error control and interim monitoring for co-primary hypotheses involving a subgroup in the Outpatient Treatment with Anti-Coronavirus Immunoglobulin (OTAC) trial","name":"articletitle","label":"Article Title"},{"value":"Contemporary Clinical Trials Communications","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.conctc.2025.101592","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Authors. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}],"article-number":"101592"}}